Additionally, the current AUA guidelines recommend that patients with prostate cancer who have a high risk of metastatic disease and negative conventional imaging may obtain prostate-specific membrane antigen positron emission tomography (PSMA PET) to evaluate for metastatic disease [5]. Here, FOLH1 is linked to prostate carcinoma.